A Phase 1B Study of RMC-6291 Plus RMC-6236 in People With Advanced Cancer


Full Title

Phase 1b, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors


Researchers want to find the best doses of RMC-6291 and RMC-6236 when given together to treat lung cancer and other types of cancer that have KRAS G12C mutations. The people in this study have advanced non-small cell lung cancer (NSCLC) or colorectal cancer with a gene mutation (change) called KRAS G12C.

RMC-6291 and RMC-6236 work in different ways to block the effects of the mutated KRAS G12C protein. This protein sends signals that cause cancer cells to grow. By blocking these signals, RMC-6291 and RMC-6236 may help slow or stop the growth of your cancer. Both drugs are taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have NSCLC or colorectal cancer that has spread even after treatment and has a KRAS G12C gene mutation.
  • Have recovered from the serious side effects of prior therapies before getting the study treatment.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Kathryn Arbour’s office at 646-608-3792.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID